Evotec AG today announced that it increases its financial guidance for the current year. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/evotec-ag-increases-its-revenue-guidance-for-2015-12
Evotec enters into licence and collaboration agreement with Pfizer Inc. in tissue fibrosis
Evotec AG today announced that it has signed an agreement on a four-year research collaboration with Pfizer Inc. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-into-licence-and-collaboration-agreement-with-pfizer-inc-in-tissue-fibrosis-5309
Evotec publishes update of its DDup Special Edition – Drug discovery services
Hamburg, Germany – 04 September 2015: Evotec AG today published its updated DDup Special edition “Drug discovery services”. This new edition outlines Evotec’s drug discovery platforms including new capacities, … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-publishes-update-of-its-ddup-special-edition—drug-discovery-services-5306
Evotec and CHDI Foundation expand ongoing collaboration to fight Huntington's disease using Evotec's expanded capabilities and footprint
Evotec AG today announced that CHDI Foundation, Inc. has extended and expanded its collaboration with Evotec through to August 2018. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-chdi-foundation-expand-ongoing-collaboration-to-fight-huntingtons-disease-using-evotecs-expanded-capabilities-and-footprint-5305
Evotec AG reports results of first half of 2015
Evotec AG today reported financial results and corporate updates for the first half of 2015. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-reports-results-of-first-half-of-2015-5303
Evotec, Apeiron Biologics and Sanofi jointly develop novel small molecule-based cancer immunotherapies
Evotec AG and Apeiron Biologics AG, a biotech company with a focus on immunological approaches to treat cancer, today announced a strategic collaboration with Sanofi to develop novel small molecule-based cancer immunotherapies. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-apeiron-biologics-and-sanofi-jointly-develop-novel-small-molecule-based-cancer-immunotherapies-5301
Sanofi and Evotec align forces to develop next generation therapies in diabetes
Evotec AG and Sanofi today announced a strategic collaboration in the field of diabetes. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/sanofi-and-evotec-align-forces-to-develop-next-generation-therapies-in-diabetes-5299
Evotec enters innovative research initiative with Gladstone Institutes and Dolby Family Ventures in Alzheimer's Disease
Evotec AG today announced that it has become part of a research initiative between a newly established for-profit company of the Gladstone Institutes called Cure Network Ventures, Inc. and Dolby Family Ventures. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-innovative-research-initiative-with-gladstone-institutes-and-dolby-family-ventures-in-alzheimers-disease-5295
Evotec's partner Roche provides initial update from Phase IIb trial in Alzheimer's disease
Evotec AG was updated today by its partner Roche on the initial results of the Phase IIb trial with Sembragiline, a MAO-B inhibitor for the treatment of Alzheimer’s disease. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotecs-partner-roche-provides-initial-update-from-phase-iib-trial-in-alzheimers-disease-5293
Evotec AG reports results of first quarter 2015
– VERY STRONG START TO 2015: 22% GROWTH OF GROUP REVENUES, MAINLY DRIVEN BY EVT EXECUTE – MAJOR MULTI-COMPONENT STRATEGIC ALLIANCE WITH SANOFI CLOSED- FULL-YEAR REVENUE GUIDANCE RAISED Hamburg, Germany – 12 May 2015: … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-reports-results-of-first-quarter-2015-5285